Breaking News Instant updates and real-time market news.

BOLD

Audentes Therapeutics

$29.53

0.36 (1.23%)

16:12
11/06/18
11/06
16:12
11/06/18
16:12

Audentes Therapeutics reports Q3 EPS 97c, consensus (88c)

As of September 30 the company had cash, cash equivalents, marketable securities and restricted cash of $285.5M, which includes approximately $3.6M of restricted cash and approximately $1.3M of long-term investments. Current cash, cash equivalents, and marketable securities are expected to fund operations into 2021.

  • 06

    Nov

  • 12

    Nov

BOLD Audentes Therapeutics
$29.53

0.36 (1.23%)

10/08/18
MZHO
10/08/18
NO CHANGE
Target $45
MZHO
Buy
Audentes data met best-case scenario, says Mizuho
Mizuho analyst Difei Yang says the Phase 1/2 clinical trial of AT132 for the treatment of XLMTM reported Friday by Audentes Therapeutics were "impressive" and met her best-case scenario expectations. Cohort one patients showing continued improvements out to week 48 and the initial cohort two patient showing rapid initial improvement at week four, Yang tells investors in a research note. Further, the safety profile remains "highly encouraging" and discussions with regulators are expected to begin in Q4, the analyst adds. She reiterates a Buy rating on Audentes with a $45 price target.
10/09/18
GUGG
10/09/18
INITIATION
GUGG
Neutral
Audentes Therapeutics initiated with a Neutral at Guggenheim
10/09/18
GUGG
10/09/18
INITIATION
GUGG
Neutral
Audentes Therapeutics initiated with a Neutral at Guggenheim
Guggenheim analyst Whitney Ijem initiated Audentes Therapeutics with a Neutral rating, saying that at current levels they believe the potential revenues are already reflected.
10/12/18
HCWC
10/12/18
NO CHANGE
Target $33
HCWC
Buy
Audentes Therapeutics price target lowered to $33 from $40 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay lowered his price target for Audentes Therapeutics to $33 after the company closed another secondary offering at $29 per share, which he notes represents a 17% discount to the January offering, which diluted shareholders by about 14%. The latest offering "leaves more than a sour taste in our mouths," Chattopadhyay tells investors in a research note. He believes Audentes had "no dire need to access the capital markets" and finds the timing and pricing of the offering "to be a little suspect." However, Chattopadhyay keeps a Buy rating on Audentes Therapeutics.

TODAY'S FREE FLY STORIES

TCON

TRACON Pharmaceuticals

$1.30

0.005 (0.39%)

08:46
11/19/18
11/19
08:46
11/19/18
08:46
Hot Stocks
TRACON Pharmaceuticals TRC102, Temodar trial does not meet primary endpoint »

TRACON Pharmaceuticals …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFR

Cullen/Frost

$101.35

0.11 (0.11%)

08:46
11/19/18
11/19
08:46
11/19/18
08:46
Conference/Events
Cullen/Frost has a conference call hosted by SunTrust »

SunTrust Analyst Demba…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

PINC

Premier

$39.60

-0.26 (-0.65%)

08:45
11/19/18
11/19
08:45
11/19/18
08:45
Recommendations
Premier analyst commentary  »

Baird sees Premier shares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAX

Baxter

$66.49

0.68 (1.03%)

, ACRX

AcelRx

$2.92

0.07 (2.46%)

08:45
11/19/18
11/19
08:45
11/19/18
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

BAX

Baxter

$66.49

0.68 (1.03%)

ACRX

AcelRx

$2.92

0.07 (2.46%)

XOP

SPDR Oil Exploration and Production Fund

$34.75

-0.055 (-0.16%)

HEAR

Turtle Beach

$15.17

0.15 (1.00%)

NWL

Newell Brands

$21.69

0.32 (1.50%)

EBIX

Ebix

$51.54

1.83 (3.68%)

CNAT

Conatus

$4.82

0.16 (3.43%)

TRVN

Trevena

$0.64

-0.0056 (-0.87%)

EMR

Emerson

$69.68

0.86 (1.25%)

HUYA

Huya

$17.68

-0.45 (-2.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Dec

  • 05

    Dec

  • 11

    Dec

BB

BlackBerry

$8.97

0.12 (1.36%)

08:43
11/19/18
11/19
08:43
11/19/18
08:43
Upgrade
BlackBerry rating change  »

BlackBerry upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FSNN

Fusion

$2.42

-0.2 (-7.63%)

08:42
11/19/18
11/19
08:42
11/19/18
08:42
Hot Stocks
Fusion awarded $720,000 cloud solutions contract from Asian fast food chain »

Fusion announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

SFIX

Stitch Fix

$26.83

-0.09 (-0.33%)

08:41
11/19/18
11/19
08:41
11/19/18
08:41
Initiation
Stitch Fix initiated  »

Stitch Fix initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Dec

CARG

CarGurus

$38.76

0.31 (0.81%)

08:41
11/19/18
11/19
08:41
11/19/18
08:41
Initiation
CarGurus initiated  »

CarGurus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Dec

ATRA

Atara Biotherapeutics

$37.28

1.46 (4.08%)

08:39
11/19/18
11/19
08:39
11/19/18
08:39
Hot Stocks
Atara Biotherapeutics announces publication of Phase 1 ATA190 results »

Atara Biotherapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Dec

MBTF

MBT Financial

$11.25

0.03 (0.27%)

, FRME

First Merchants

$41.23

0.06 (0.15%)

08:39
11/19/18
11/19
08:39
11/19/18
08:39
Upgrade
MBT Financial, First Merchants rating change  »

Sandler O'Neill…

MBTF

MBT Financial

$11.25

0.03 (0.27%)

FRME

First Merchants

$41.23

0.06 (0.15%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADVM

Adverum Biotechnologies

$3.83

0.095 (2.55%)

08:35
11/19/18
11/19
08:35
11/19/18
08:35
Hot Stocks
Adverum Biotechnologies announces first patient dosed in OPTIC trial »

Adverum Biotechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

MLNX

Mellanox

$93.83

0.34 (0.36%)

, LN

Line Corp.

$28.48

-0.23 (-0.80%)

08:35
11/19/18
11/19
08:35
11/19/18
08:35
Hot Stocks
Line Corp. collaborates with Mellanox, Cumulus Networks for messaging platform »

Mellanox Technologies…

MLNX

Mellanox

$93.83

0.34 (0.36%)

LN

Line Corp.

$28.48

-0.23 (-0.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

08:35
11/19/18
11/19
08:35
11/19/18
08:35
General news
Oil Action: NYMEX crude »

Oil Action: NYMEX crude…

FRME

First Merchants

$41.23

0.06 (0.15%)

08:33
11/19/18
11/19
08:33
11/19/18
08:33
Upgrade
First Merchants rating change  »

Sandler ONeill upgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PVH

PVH Corp.

$115.51

-1.84 (-1.57%)

08:33
11/19/18
11/19
08:33
11/19/18
08:33
Recommendations
PVH Corp. analyst commentary  »

PVH Corp. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

CLX

Clorox

$162.02

1.51 (0.94%)

08:31
11/19/18
11/19
08:31
11/19/18
08:31
Conference/Events
Clorox management to meet with Jefferies »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

HP

Helmerich & Payne

$62.59

2.54 (4.23%)

08:31
11/19/18
11/19
08:31
11/19/18
08:31
Upgrade
Helmerich & Payne rating change  »

Helmerich & Payne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INGR

Ingredion

$101.29

1.56 (1.56%)

08:30
11/19/18
11/19
08:30
11/19/18
08:30
Recommendations
Ingredion analyst commentary  »

Ingredion price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INXN

Interxion

$64.10

0.62 (0.98%)

08:30
11/19/18
11/19
08:30
11/19/18
08:30
Conference/Events
Interxion management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

FCSC

Fibrocell Science

$2.08

0.015 (0.73%)

, LPNT

LifePoint

$65.00

(0.00%)

08:30
11/19/18
11/19
08:30
11/19/18
08:30
Options
Five option delistings on November 19th »

Option delistings…

FCSC

Fibrocell Science

$2.08

0.015 (0.73%)

LPNT

LifePoint

$65.00

(0.00%)

NYRT

New York REIT

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NHLD

National Holdings Corp

$2.96

(0.00%)

08:30
11/19/18
11/19
08:30
11/19/18
08:30
Hot Stocks
Breaking Hot Stocks news story on National Holdings Corp »

National Holdings Corp…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENDP

Endo

$12.70

-0.035 (-0.27%)

08:29
11/19/18
11/19
08:29
11/19/18
08:29
Conference/Events
Endo management to meet with Cantor Fitzgerald »

Endo holds a Phase 3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 27

    Nov

SIX

Six Flags

$59.79

1 (1.70%)

08:27
11/19/18
11/19
08:27
11/19/18
08:27
Recommendations
Six Flags analyst commentary  »

Six Flags checks show Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACBI

Atlantic Capital

$17.32

0.04 (0.23%)

08:27
11/19/18
11/19
08:27
11/19/18
08:27
Upgrade
Atlantic Capital rating change  »

Atlantic Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

NVEE

NV5 Global

$73.44

-0.23 (-0.31%)

08:27
11/19/18
11/19
08:27
11/19/18
08:27
Hot Stocks
NV5 Global awarded $17M location, survey services contract from NCDOT »

NV5 Global announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.